Edwards Lifesciences - EW Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings or view top-rated stocks.

18 brokers have issued 12 month price targets for Edwards Lifesciences' stock. Their EW share price forecasts range from $66.00 to $134.00. On average, they predict the company's stock price to reach $88.95 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 8.2% and is now trading at $80.76.
View the best growth stocks for 2023 here.

Edwards Lifesciences saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 12,770,000 shares, an increase of 6.8% from the February 13th total of 11,960,000 shares. Based on an average daily volume of 3,940,000 shares, the short-interest ratio is presently 3.2 days. Currently, 2.1% of the company's stock are sold short.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Tuesday, January, 31st. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.03. The medical research company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 26.05% and a net margin of 28.27%. The business's quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.51 EPS.
Read the conference call transcript.

ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Goldman Sachs Future Health Care Equity ETF (GDOC), ETC 6 Meridian Quality Growth ETF (SXQG), Global X Aging Population ETF (AGNG), BNY Mellon Sustainable US Equity ETF (BKUS), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and Inspire 100 ETF (BIBL).

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.45-$2.60 for the period, compared to the consensus estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (3.60%), Moneta Group Investment Advisors LLC (2.49%), Brown Advisory Inc. (2.32%), Geode Capital Management LLC (1.96%), Norges Bank (1.43%) and Amundi (1.31%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $80.76.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $48.95 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.44 on an earnings per share basis.

The company employs 17,300 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.